Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
BERKELEY, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer’s 26th Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected]
